However, the advent of CFTR modulators, particularly the triple‐combination therapy elexacaftor/tezacaftor/ivacaftor (ETI), has dramatically changed the prognosis and management of CF by directly targeting CFTR′s protein defects. The gene discussed is CFTR; the disease is cystic fibrosis.